Realizing the promise.

We are at the cusp of a revolution in medicine. Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs.

null

Aoife M. Brennan, MB, ChB

President, Chief Executive Officer, Chief Medical Officer
null

Todd Shegog

Chief Financial Officer
null

Paul Miller, PhD

Chief Scientific Officer
null

Caroline B. Kurtz, PhD

Head of Translational Sciences and Product Development
null

Adam Thomas

Chief Human Resources Officer
null

Maiken Keson-Brookes

General Counsel
null

Antoine Awad

Head of Technical Operations